Should endometrial clear cell carcinoma be classified as type II endometrial carcinoma?

Hyo Sook Bae, Hyesun Kim, Sun Young Kwon, Kyu Rae Kim, Jae Yun Song, Insun Kim

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Endometrial clear cell carcinomas (ECCCs) are considered to be Type II endometrial carcinomas, like uterine serous adenocarcinoma (SCA), and therefore aggressive clinical management is indicated. However, according to the limited clinical, immunohistochemical, and molecular data available in the literature, ECCCs show overlapping features of SCA and endometrioid adenocarcinomas. Therefore, questions regarding their designation as the Type II carcinomas have been raised. We performed immunohistochemical staining for hepatocyte nuclear factor-1β and napsin A for the histologic confirmation of clear cell carcinoma (CCC), and analyzed immunohistochemical findings for estrogen receptor, progesterone receptor, HER2/neu, p53, p16, ARID1A, PTEN, DNA mismatch-repair proteins along with other prognostic factors. We performed DNA sequencing for the K-RAS, BRAF, PIK3CA, and PTEN genes for 16 pure CCCs. No patients with pure CCC experienced recurrent disease or died of the disease (0/16, 0%). ECCCs had SCA-like features with rare expression of estrogen receptor/progesterone receptor (18.8%/6.3%) and no K-RAS mutations, intermediate features regarding expressions of p53 (37.5%) and p16 (25%), and endometrioid adenocarcinoma-like features regarding losses of PTEN (81.3%), ARID1A (25%) and mismatch-repair protein (68.8%), expression of microsatellite instability-high (25%), HER2/neu (12.5%), and PIK3CA mutations (18.8%). Pure ECCC should not be regarded as Type II carcinoma, because it shares the immunohistochemical and molecular characteristics of Type I endometrioid adenocarcinoma and Type II SCA.

Original languageEnglish
Pages (from-to)74-84
Number of pages11
JournalInternational Journal of Gynecological Pathology
Volume34
Issue number1
DOIs
Publication statusPublished - 2015 Jan 14

Fingerprint

Endometrial Neoplasms
Carcinoma
Endometrioid Carcinoma
Adenocarcinoma
DNA Mismatch Repair
Progesterone Receptors
Estrogen Receptors
Hepatocyte Nuclear Factor 1
Microsatellite Instability
Mutation
DNA Sequence Analysis
Proteins
Staining and Labeling
Genes

Keywords

  • Clear cell adenocarcinoma
  • DNA sequencing
  • Endometrial carcinoma
  • Endometrioid adenocarcinoma
  • Immunohistochemistry

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Obstetrics and Gynaecology

Cite this

Should endometrial clear cell carcinoma be classified as type II endometrial carcinoma? / Bae, Hyo Sook; Kim, Hyesun; Kwon, Sun Young; Kim, Kyu Rae; Song, Jae Yun; Kim, Insun.

In: International Journal of Gynecological Pathology, Vol. 34, No. 1, 14.01.2015, p. 74-84.

Research output: Contribution to journalArticle

Bae, Hyo Sook ; Kim, Hyesun ; Kwon, Sun Young ; Kim, Kyu Rae ; Song, Jae Yun ; Kim, Insun. / Should endometrial clear cell carcinoma be classified as type II endometrial carcinoma?. In: International Journal of Gynecological Pathology. 2015 ; Vol. 34, No. 1. pp. 74-84.
@article{e9e164f88166486cbb41b51290069f23,
title = "Should endometrial clear cell carcinoma be classified as type II endometrial carcinoma?",
abstract = "Endometrial clear cell carcinomas (ECCCs) are considered to be Type II endometrial carcinomas, like uterine serous adenocarcinoma (SCA), and therefore aggressive clinical management is indicated. However, according to the limited clinical, immunohistochemical, and molecular data available in the literature, ECCCs show overlapping features of SCA and endometrioid adenocarcinomas. Therefore, questions regarding their designation as the Type II carcinomas have been raised. We performed immunohistochemical staining for hepatocyte nuclear factor-1β and napsin A for the histologic confirmation of clear cell carcinoma (CCC), and analyzed immunohistochemical findings for estrogen receptor, progesterone receptor, HER2/neu, p53, p16, ARID1A, PTEN, DNA mismatch-repair proteins along with other prognostic factors. We performed DNA sequencing for the K-RAS, BRAF, PIK3CA, and PTEN genes for 16 pure CCCs. No patients with pure CCC experienced recurrent disease or died of the disease (0/16, 0{\%}). ECCCs had SCA-like features with rare expression of estrogen receptor/progesterone receptor (18.8{\%}/6.3{\%}) and no K-RAS mutations, intermediate features regarding expressions of p53 (37.5{\%}) and p16 (25{\%}), and endometrioid adenocarcinoma-like features regarding losses of PTEN (81.3{\%}), ARID1A (25{\%}) and mismatch-repair protein (68.8{\%}), expression of microsatellite instability-high (25{\%}), HER2/neu (12.5{\%}), and PIK3CA mutations (18.8{\%}). Pure ECCC should not be regarded as Type II carcinoma, because it shares the immunohistochemical and molecular characteristics of Type I endometrioid adenocarcinoma and Type II SCA.",
keywords = "Clear cell adenocarcinoma, DNA sequencing, Endometrial carcinoma, Endometrioid adenocarcinoma, Immunohistochemistry",
author = "Bae, {Hyo Sook} and Hyesun Kim and Kwon, {Sun Young} and Kim, {Kyu Rae} and Song, {Jae Yun} and Insun Kim",
year = "2015",
month = "1",
day = "14",
doi = "10.1097/PGP.0000000000000111",
language = "English",
volume = "34",
pages = "74--84",
journal = "International Journal of Gynecological Pathology",
issn = "0277-1691",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Should endometrial clear cell carcinoma be classified as type II endometrial carcinoma?

AU - Bae, Hyo Sook

AU - Kim, Hyesun

AU - Kwon, Sun Young

AU - Kim, Kyu Rae

AU - Song, Jae Yun

AU - Kim, Insun

PY - 2015/1/14

Y1 - 2015/1/14

N2 - Endometrial clear cell carcinomas (ECCCs) are considered to be Type II endometrial carcinomas, like uterine serous adenocarcinoma (SCA), and therefore aggressive clinical management is indicated. However, according to the limited clinical, immunohistochemical, and molecular data available in the literature, ECCCs show overlapping features of SCA and endometrioid adenocarcinomas. Therefore, questions regarding their designation as the Type II carcinomas have been raised. We performed immunohistochemical staining for hepatocyte nuclear factor-1β and napsin A for the histologic confirmation of clear cell carcinoma (CCC), and analyzed immunohistochemical findings for estrogen receptor, progesterone receptor, HER2/neu, p53, p16, ARID1A, PTEN, DNA mismatch-repair proteins along with other prognostic factors. We performed DNA sequencing for the K-RAS, BRAF, PIK3CA, and PTEN genes for 16 pure CCCs. No patients with pure CCC experienced recurrent disease or died of the disease (0/16, 0%). ECCCs had SCA-like features with rare expression of estrogen receptor/progesterone receptor (18.8%/6.3%) and no K-RAS mutations, intermediate features regarding expressions of p53 (37.5%) and p16 (25%), and endometrioid adenocarcinoma-like features regarding losses of PTEN (81.3%), ARID1A (25%) and mismatch-repair protein (68.8%), expression of microsatellite instability-high (25%), HER2/neu (12.5%), and PIK3CA mutations (18.8%). Pure ECCC should not be regarded as Type II carcinoma, because it shares the immunohistochemical and molecular characteristics of Type I endometrioid adenocarcinoma and Type II SCA.

AB - Endometrial clear cell carcinomas (ECCCs) are considered to be Type II endometrial carcinomas, like uterine serous adenocarcinoma (SCA), and therefore aggressive clinical management is indicated. However, according to the limited clinical, immunohistochemical, and molecular data available in the literature, ECCCs show overlapping features of SCA and endometrioid adenocarcinomas. Therefore, questions regarding their designation as the Type II carcinomas have been raised. We performed immunohistochemical staining for hepatocyte nuclear factor-1β and napsin A for the histologic confirmation of clear cell carcinoma (CCC), and analyzed immunohistochemical findings for estrogen receptor, progesterone receptor, HER2/neu, p53, p16, ARID1A, PTEN, DNA mismatch-repair proteins along with other prognostic factors. We performed DNA sequencing for the K-RAS, BRAF, PIK3CA, and PTEN genes for 16 pure CCCs. No patients with pure CCC experienced recurrent disease or died of the disease (0/16, 0%). ECCCs had SCA-like features with rare expression of estrogen receptor/progesterone receptor (18.8%/6.3%) and no K-RAS mutations, intermediate features regarding expressions of p53 (37.5%) and p16 (25%), and endometrioid adenocarcinoma-like features regarding losses of PTEN (81.3%), ARID1A (25%) and mismatch-repair protein (68.8%), expression of microsatellite instability-high (25%), HER2/neu (12.5%), and PIK3CA mutations (18.8%). Pure ECCC should not be regarded as Type II carcinoma, because it shares the immunohistochemical and molecular characteristics of Type I endometrioid adenocarcinoma and Type II SCA.

KW - Clear cell adenocarcinoma

KW - DNA sequencing

KW - Endometrial carcinoma

KW - Endometrioid adenocarcinoma

KW - Immunohistochemistry

UR - http://www.scopus.com/inward/record.url?scp=84918768074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918768074&partnerID=8YFLogxK

U2 - 10.1097/PGP.0000000000000111

DO - 10.1097/PGP.0000000000000111

M3 - Article

C2 - 25473756

AN - SCOPUS:84918768074

VL - 34

SP - 74

EP - 84

JO - International Journal of Gynecological Pathology

JF - International Journal of Gynecological Pathology

SN - 0277-1691

IS - 1

ER -